Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Pediatric Genomic Medicine, |
RCV000514917 | SCV000610968 | likely pathogenic | not provided | 2017-04-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001231241 | SCV001403754 | pathogenic | Peroxisome biogenesis disorder | 2023-09-29 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Trp430Glyfs*20) in the PEX6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PEX6 are known to be pathogenic (PMID: 10408779, 21031596, 31831025). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with PEX6-related conditions. ClinVar contains an entry for this variant (Variation ID: 446026). For these reasons, this variant has been classified as Pathogenic. |
Prevention |
RCV004551655 | SCV004111313 | pathogenic | PEX6-related disorder | 2023-08-13 | criteria provided, single submitter | clinical testing | The PEX6 c.1287delC variant is predicted to result in a frameshift and premature protein termination (p.Trp430Glyfs*20). This variant was reported in the compound heterozygous state in two siblings with peroxisomal disorders (Gagnon et al. 2023. PubMed ID: 36649687). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Frameshift variants in PEX6 are expected to be pathogenic. This variant is interpreted as pathogenic. |
Baylor Genetics | RCV003476210 | SCV004201622 | likely pathogenic | Heimler syndrome 2 | 2023-12-08 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001276617 | SCV001463069 | likely pathogenic | Zellweger spectrum disorders | 2020-09-16 | no assertion criteria provided | clinical testing |